Table SI.Quality assessment of included single-arm clinical trials.

Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Total
Xiaorong Zhong, 2022	2	1	2	2	0	2	2	1	12
Zhenzhen Liu, 2022	2	1	2	2	0	2	2	2	13
Wenjin Yin, 2022	2	1	2	2	0	2	2	2	13
JunchengXuhong, 2020	2	1	2	2	0	2	2	1	12
Qiyun Shi, 2022	2	1	2	2	0	2	1	1	11

Q1, A clearly stated aim: the question addressed should be precise and relevant in the light of available literature; Q2, Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the criteria for inclusion) have been included in the study during the study period (no exclusion or detailsabout the reasons for exclusion); Q3, Prospective collection of data: data were collected according to a protocol established before the beginning of the study;Q4, Endpoints appropriate to the aim of the study: unambiguous explanation of the criteria used to evaluate the main outcome which should be in accordance with the question addressed by thestudy. Also, the endpoints should be assessed on an intention-to-treat basis; Q5, Unbiased assessment of the study endpoint: blind evaluation of objective endpoints and double-blind evaluation of subjective endpoints. Otherwise the reasons for not blinding should bestated; Q6, Follow-up period appropriate to the aim of the study: the follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events; Q7, Loss to follow up less than 5%: all patients should be included in the follow up. Otherwise, the proportion lost to follow up should not exceed the proportion experiencing the major endpoint; Q8, Prospective calculation of the study size: information of the size of detectable difference of interest with a calculation of 95% confidence interval, according to the expected incidence of theoutcome event, and information about the level for statistical significance and estimates of power when comparing the outcomes.The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate).

Table SII.P-value of Egger's test of treatment-related adverse events and pooled pathology complete rate.

Treatment-related adverse events	P-value of Egger's test (any grades)	(≥3grades)		P-value of Egger's test
Diarrhea	0.160	0.472	PCR	0.081
Anemia	0.829	0.749	PCR HR(-)	0.106
Vomiting	0.412	0.213	PCR HR(+)	0.188
Leucopenia	0.267	0.719		
Neutropenia	0.260	0.620		
Nausea	0.719	0.619		
Fatigue	0.520	0.384		
ALT increased	0.885	0.690		
Rash	0.720	0.580		
AST increased	0.878	0.417		
Creatinine increased	0.287	0.916		

ALT, alanine transaminase; AST, aspartate transaminase; PCR, pathological complete response; HR, hormone receptor.